Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates

© Copyright 2017 Wolters Kluwer Health, Inc. All rights reserved. Background: Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates. We evaluated current World Health Organization (WHO) weight-band NVP prophylactic dosing recommendations and investigated optima...

Full description

Saved in:
Bibliographic Details
Main Authors: Cressey T., Punyawudho B., Le Coeur S., Jourdain G., Saenjum C., Capparelli E., Jittayanun K., Phanomcheong S., Luvira A., Borkird T., Puangsombat A., Aarons L., Sukrakanchana P., Urien S., Lallemant M., Sangsawang S., Achalapong J., Preedisripipat K., Putiyanun C., Wanchaitanawong V., Yuthavisuthi P., Ngampiyaskul C., Kanjanavikai P., Chotivanich N., Hongsiriwon S., Suwankornsakul W., Sreshthatat P., Kanjanasing A., Kwanchaipanich R., Rawangban B., Santadusit S., Jarupanich T., Warachit B., Siriwachirachai T., Rojanakarin P., Vivatpatanakul K., Hanpinitsak S., Wanasiri P., Srirojana S., Kongpanichkul R., Bunjongpak S., Sabsanong P., Liampongsabuddhi P., Pongdetudom K., Khamja P., Akarathum N., Phonin S., Limpitikul W., Jungpipun J., Petprakorp R., Mahattanan S., Kotchawet S., Pilalai T.
Format: Journal
Published: 2017
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85025687300&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/40175
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-40175
record_format dspace
spelling th-cmuir.6653943832-401752017-09-28T04:08:06Z Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates Cressey T. Punyawudho B. Le Coeur S. Jourdain G. Saenjum C. Capparelli E. Jittayanun K. Phanomcheong S. Luvira A. Borkird T. Puangsombat A. Aarons L. Sukrakanchana P. Urien S. Lallemant M. Sangsawang S. Achalapong J. Preedisripipat K. Putiyanun C. Wanchaitanawong V. Yuthavisuthi P. Ngampiyaskul C. Kanjanavikai P. Chotivanich N. Hongsiriwon S. Suwankornsakul W. Sreshthatat P. Kanjanasing A. Kwanchaipanich R. Rawangban B. Santadusit S. Jarupanich T. Warachit B. Siriwachirachai T. Rojanakarin P. Vivatpatanakul K. Hanpinitsak S. Wanasiri P. Srirojana S. Kongpanichkul R. Bunjongpak S. Sabsanong P. Liampongsabuddhi P. Pongdetudom K. Khamja P. Akarathum N. Phonin S. Limpitikul W. Jungpipun J. Petprakorp R. Mahattanan S. Kotchawet S. Pilalai T. © Copyright 2017 Wolters Kluwer Health, Inc. All rights reserved. Background: Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates. We evaluated current World Health Organization (WHO) weight-band NVP prophylactic dosing recommendations and investigated optimal therapeutic NVP dosing for neonates. Methods: The PHPT-5 study in Thailand assessed the efficacy of "Perinatal Antiretroviral Intensification" to prevent mother-to-child transmission of HIV in women with < 8 weeks of antiretroviral treatment before delivery (NCT01511237). Infants received a 2-week course of zidovudine/lamivudine/NVP (NVP syrup/once daily: 2 mg/kg for 7 days; then 4 mg/kg for 7 days). Infant samples were assessed during the first 2 weeks of life. NVP population pharmacokinetics (PK) parameters were estimated using nonlinear mixed-effects models. Simulations were performed to estimate the probability of achieving target NVP trough concentrations for prophylaxis ( > 0.10 mg/L) and for therapeutic efficacy ( > 3.0 mg/L) using different infant dosing strategies. Results: Sixty infants (55% male) were included. At birth, median (range) weight was 2.9 (2.3-3.6) kg. NVP concentrations were best described by a 1-compartment PK model. Infant weight and postnatal age influenced NVP PK parameters. Based on simulations for a 3-kg infant, ≥92% would have an NVP trough > 0.1 mg/L after 48 hours through 2 weeks using the PHPT-5 and WHO-dosing regimens. For NVP-based therapy, a 6-mg/kg twice daily dose produced a trough > 3.0 mg/L in 87% of infants at 48 hours and 80% at 2 weeks. Conclusion: WHO weight-band prophylactic guidelines achieved target concentrations. Starting NVP 6 mg/kg twice daily from birth is expected to achieve therapeutic concentrations during the first 2 weeks of life. 2017-09-28T04:08:06Z 2017-09-28T04:08:06Z 5 Journal 15254135 2-s2.0-85025687300 10.1097/QAI.0000000000001447 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85025687300&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/40175
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
description © Copyright 2017 Wolters Kluwer Health, Inc. All rights reserved. Background: Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates. We evaluated current World Health Organization (WHO) weight-band NVP prophylactic dosing recommendations and investigated optimal therapeutic NVP dosing for neonates. Methods: The PHPT-5 study in Thailand assessed the efficacy of "Perinatal Antiretroviral Intensification" to prevent mother-to-child transmission of HIV in women with < 8 weeks of antiretroviral treatment before delivery (NCT01511237). Infants received a 2-week course of zidovudine/lamivudine/NVP (NVP syrup/once daily: 2 mg/kg for 7 days; then 4 mg/kg for 7 days). Infant samples were assessed during the first 2 weeks of life. NVP population pharmacokinetics (PK) parameters were estimated using nonlinear mixed-effects models. Simulations were performed to estimate the probability of achieving target NVP trough concentrations for prophylaxis ( > 0.10 mg/L) and for therapeutic efficacy ( > 3.0 mg/L) using different infant dosing strategies. Results: Sixty infants (55% male) were included. At birth, median (range) weight was 2.9 (2.3-3.6) kg. NVP concentrations were best described by a 1-compartment PK model. Infant weight and postnatal age influenced NVP PK parameters. Based on simulations for a 3-kg infant, ≥92% would have an NVP trough > 0.1 mg/L after 48 hours through 2 weeks using the PHPT-5 and WHO-dosing regimens. For NVP-based therapy, a 6-mg/kg twice daily dose produced a trough > 3.0 mg/L in 87% of infants at 48 hours and 80% at 2 weeks. Conclusion: WHO weight-band prophylactic guidelines achieved target concentrations. Starting NVP 6 mg/kg twice daily from birth is expected to achieve therapeutic concentrations during the first 2 weeks of life.
format Journal
author Cressey T.
Punyawudho B.
Le Coeur S.
Jourdain G.
Saenjum C.
Capparelli E.
Jittayanun K.
Phanomcheong S.
Luvira A.
Borkird T.
Puangsombat A.
Aarons L.
Sukrakanchana P.
Urien S.
Lallemant M.
Sangsawang S.
Achalapong J.
Preedisripipat K.
Putiyanun C.
Wanchaitanawong V.
Yuthavisuthi P.
Ngampiyaskul C.
Kanjanavikai P.
Chotivanich N.
Hongsiriwon S.
Suwankornsakul W.
Sreshthatat P.
Kanjanasing A.
Kwanchaipanich R.
Rawangban B.
Santadusit S.
Jarupanich T.
Warachit B.
Siriwachirachai T.
Rojanakarin P.
Vivatpatanakul K.
Hanpinitsak S.
Wanasiri P.
Srirojana S.
Kongpanichkul R.
Bunjongpak S.
Sabsanong P.
Liampongsabuddhi P.
Pongdetudom K.
Khamja P.
Akarathum N.
Phonin S.
Limpitikul W.
Jungpipun J.
Petprakorp R.
Mahattanan S.
Kotchawet S.
Pilalai T.
spellingShingle Cressey T.
Punyawudho B.
Le Coeur S.
Jourdain G.
Saenjum C.
Capparelli E.
Jittayanun K.
Phanomcheong S.
Luvira A.
Borkird T.
Puangsombat A.
Aarons L.
Sukrakanchana P.
Urien S.
Lallemant M.
Sangsawang S.
Achalapong J.
Preedisripipat K.
Putiyanun C.
Wanchaitanawong V.
Yuthavisuthi P.
Ngampiyaskul C.
Kanjanavikai P.
Chotivanich N.
Hongsiriwon S.
Suwankornsakul W.
Sreshthatat P.
Kanjanasing A.
Kwanchaipanich R.
Rawangban B.
Santadusit S.
Jarupanich T.
Warachit B.
Siriwachirachai T.
Rojanakarin P.
Vivatpatanakul K.
Hanpinitsak S.
Wanasiri P.
Srirojana S.
Kongpanichkul R.
Bunjongpak S.
Sabsanong P.
Liampongsabuddhi P.
Pongdetudom K.
Khamja P.
Akarathum N.
Phonin S.
Limpitikul W.
Jungpipun J.
Petprakorp R.
Mahattanan S.
Kotchawet S.
Pilalai T.
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates
author_facet Cressey T.
Punyawudho B.
Le Coeur S.
Jourdain G.
Saenjum C.
Capparelli E.
Jittayanun K.
Phanomcheong S.
Luvira A.
Borkird T.
Puangsombat A.
Aarons L.
Sukrakanchana P.
Urien S.
Lallemant M.
Sangsawang S.
Achalapong J.
Preedisripipat K.
Putiyanun C.
Wanchaitanawong V.
Yuthavisuthi P.
Ngampiyaskul C.
Kanjanavikai P.
Chotivanich N.
Hongsiriwon S.
Suwankornsakul W.
Sreshthatat P.
Kanjanasing A.
Kwanchaipanich R.
Rawangban B.
Santadusit S.
Jarupanich T.
Warachit B.
Siriwachirachai T.
Rojanakarin P.
Vivatpatanakul K.
Hanpinitsak S.
Wanasiri P.
Srirojana S.
Kongpanichkul R.
Bunjongpak S.
Sabsanong P.
Liampongsabuddhi P.
Pongdetudom K.
Khamja P.
Akarathum N.
Phonin S.
Limpitikul W.
Jungpipun J.
Petprakorp R.
Mahattanan S.
Kotchawet S.
Pilalai T.
author_sort Cressey T.
title Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates
title_short Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates
title_full Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates
title_fullStr Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates
title_full_unstemmed Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates
title_sort assessment of nevirapine prophylactic and therapeutic dosing regimens for neonates
publishDate 2017
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85025687300&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/40175
_version_ 1681421761426489344